" class="no-js "lang="en-US"> Aamir Malik - Medtech Alert
Thursday, July 31, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Aamir Malik

Aamir Malik

About Aamir Malik

I am the Co-Managing Partner of McKinsey & Company’s United States Office, and a Senior Partner in our global Pharmaceuticals & Medical Products Practice where I support global healthcare sector leaders in the U.S., Europe, Asia and Latin America.

Related Story

Appointments

 Pfizer Completes Acquisition of Biohaven Pharmaceuticals | Pharmtech Focus

Pfizer Completes Acquisition of Biohaven Pharmaceuticals

October 4 2022

Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding […]

Appointments

 Pfizer Announces New Chief Business Innovation Officer Aamir Malik | Pharmtech Focus

Pfizer Announces New Chief Business Innovation Officer Aamir Malik

August 27 2021

Pfizer Inc. (NYSE: PFE) today announced that Aamir Malik has joined the company as Executive […]